Navigation Links
United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
Date:3/31/2017

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 31, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Patent and Trademark's Office (USPTO) Patent Trial and Appeal Board (PTAB) issued a Final Written Decision in connection with the inter partes review (IPR) of United Therapeutics' U.S. Patent No. 8,497,393 (the '393 patent). The PTAB found that all claims of the '393 patent are not patentable. United Therapeutics is evaluating its options, including the possibility of immediately exercising its right of appeal to the U.S. Court of Appeals for the Federal Circuit or first requesting a rehearing before the PTAB. The '393 patent remains valid and enforceable until appeals have been exhausted.

By way of background, the '393 patent claims, among other things, treprostinil produced using an improved method and is listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations publication, also known as the Orange Book, for Remodulin® (treprostinil) Injection, Tyvaso® (treprostinil) Inhalation Solution, and Orenitram® (treprostinil) Extended-Release Tablets. United Therapeutics is currently asserting the '393 patent (along with several other patents) against Watson Laboratories, Inc. and Actavis Laboratories FL, Inc. in connection with their efforts to obtain approval to market generic copies of Tyvaso and Orenitram, respectively. The Watson and Actavis cases are scheduled for trial in September 2017 and February 2018, respectively. SteadyMed, Ltd. initiated the IPR in October 2015, and has reported plans to file for FDA approval of its Trevyent® treprostinil product in the second quarter of 2017.

United Therapeutics intends to continue vigorously defending the '393 patent, but even if the ultimate result is unfavorable, United Therapeutics has other patents claiming subject matter similar to the '393 patent and with the same expiration date (December 2028). Specifically, in the last month, the USPTO awarded United Therapeutics two additional patents related to the '393 patent, U.S. Patent Nos. 9,593,066 and 9,604,901. United Therapeutics prosecuted the applications that resulted in these new patents in parallel with the '393 patent IPR and presented claims addressing the invalidity arguments raised by SteadyMed in the IPR and Watson and Actavis in the ongoing litigations. The USPTO allowed the new patent claims with full knowledge of the IPR, the invalidity arguments presented therein, and the invalidity arguments raised by Watson and Actavis in connection with the '393 patent. Thus, United Therapeutics anticipates that these new patents should be less susceptible to challenge than the '393 patent. United Therapeutics has listed both these new patents in the Orange Book for Remodulin, Tyvaso, and Orenitram.     

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the possibility of United Therapeutics appealing the PTAB decision, United Therapeutics' intent to continue vigorously defending the '393 patent, United Therapeutics' belief that the two newly issued patents should be less susceptible to challenge than the '393 patent, and the impact of the two newly-issued patents on the timing of market entry for Trevyent. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. These risks and uncertainties include, among others, United Therapeutics' plans and ability to defend its intellectual property against challenges from generic companies and from SteadyMed, and such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of March 31, 2017, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-therapeutics-announces-decision-from-patent-trial-and-appeal-board-and-issuance-of-new-patents-300432711.html


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel
2. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
3. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
4. SoundConnect Announces Lync Release in the United States
5. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
6. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
9. Prevagen® is the Number One Branded Memory Supplement in the United States
10. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
11. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... YORK (PRWEB) , ... May 22, 2019 , ... ... has closed a $8 million Series A funding round co-led by Astanor Ventures ... Empire State Development Fund and iSelect Fund . The company has ...
(Date:5/14/2019)... ... May 14, 2019 , ... Gateway Genomics , a leading ... space from 2,500 to 5,000 square feet. , “This past year has seen ... says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, which is mailed directly ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... REPROCELL USA Inc. has demonstrated its ability to provide various services and ... to enhance customer satisfaction through the effective implementation of its quality management ...
(Date:4/25/2019)... ... ... is an albino, deaf Great Dane. His owners rescued him when he was four months ... his hearing impairment, he was always an active and playful pup. Frank bonded with his ... As the two grew, playtime became rougher and Frank ended up injuring his right rear ...
Breaking Biology Technology:
(Date:6/6/2019)... CITY (PRWEB) , ... June 05, 2019 , ... ... packaging, announces the opening of a new network station and service center in ... — and 12th in the world — with more than $1.75 billion in ...
(Date:6/4/2019)... ... June 04, 2019 , ... Harper was three years old ... revealed severe elbow dysplasia, which caused painful osteoarthritis in the joints. She was ... parents were heartbroken. , The surgical specialist, Dr. Christopher Eich of Southern California ...
(Date:6/1/2019)... ... May 31, 2019 , ... The University of Vermont ... in BioFactura’s $6M Series B Financing Round. , “With the commitment from ... bring significant financial and business resources to bear as we advance our biopharmaceutical ...
Breaking Biology News(10 mins):